Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, University of Minnesota School of Medicine, Minneapolis, MN, USA.
Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Adv Exp Med Biol. 2021;1330:113-123. doi: 10.1007/978-3-030-73359-9_7.
Ovarian cancer remains the leading cause of death from gynecologic malignancy in the Western world. Tumors are comprised of heterogeneous populations of various cancer, immune, and stromal cells; it is hypothesized that rare cancer stem cells within these subpopulations lead to disease recurrence and treatment resistance. Technological advances now allow for the analysis of tumor genomes and transcriptomes at the single-cell level, which provides the resolution to potentially identify these rare cancer stem cells within the larger tumor.In this chapter, we review the evolution of next-generation RNA sequencing techniques, the methodology of single-cell isolation and sequencing, sequencing data analysis, and the potential applications in ovarian cancer. We also summarize the current published work using single-cell sequencing in ovarian cancer.By utilizing this novel technique to characterize the gene expression of rare subpopulations, new targets and treatment pathways may be identified in ovarian cancer to change treatment paradigms.
卵巢癌仍然是西方妇科恶性肿瘤死亡的主要原因。肿瘤由各种癌症、免疫和基质细胞组成的异质群体组成；据推测，这些亚群中的稀有癌症干细胞导致疾病复发和治疗耐药。技术进步现在允许在单细胞水平上分析肿瘤的基因组和转录组，这为潜在地鉴定这些较大肿瘤中的稀有癌症干细胞提供了分辨率。在本章中，我们回顾了下一代 RNA 测序技术的发展，单细胞分离和测序的方法学，测序数据分析以及在卵巢癌中的潜在应用。我们还总结了目前使用卵巢癌单细胞测序的已发表工作。通过利用这项新技术来描述稀有亚群的基因表达，可能会在卵巢癌中发现新的靶点和治疗途径，从而改变治疗模式。
